PKU HealthCare Corp., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Peking University Pharmaceutical Co., Ltd. (securities abbreviation: Peking University Pharmaceutical; securities code: SZ. 000788) is a core member enterprise of the New Founder Group's medical and pharmaceutical industry. The company has a history of over 50 years in pharmaceutical manufacturing, and is a key backbone enterprise of Chinese medicine, a national innovation pilot enterprise, a key high-tech enterprise of the National Torch Plan, a national demonstration enterprise for the integration of industrialization and standardization, and a technology innovation demonstration enterprise in Chongqing. Peking University Pharmaceutical has a comprehensive quality assurance system, with products covering more than 10 major categories, including anti-tumor, psychiatric, cardiovascular, immunosuppressive, antimicrobial, antipyretic and analgesic, and over 100 varieties. At the same time, a technology core system integrating independent intellectual property rights, innovative technology, and technological innovation has been established. The research and development field focuses on innovative drugs such as anti infective, psychiatric, and analgesic drugs, high-end generic drugs, and large market varieties, providing a continuously optimized product structure and competitiveness for enterprise development. At present, the company's marketing center has established a nationwide pharmaceutical sales network and an efficient pharmaceutical distribution system, covering drug sales, pharmaceutical circulation, hospital centralized procurement, and supply chain custody. In the future, Peking University Pharmaceutical will be committed to building a pharmaceutical technology enterprise with international capabilities that combines imitation and innovation. It will continuously consolidate its endogenous foundation, actively promote external development, introduce strategic cooperation, focus on improving core R&D capabilities, form a group of key product groups, and become a pharmaceutical listed company with distinct industry characteristics, unique competitive advantages, and important status and influence in the Chinese pharmaceutical industry. |
| Headquarter | Chongqing |
| Establish Date | 5/18/1993 |
| Listed Code | 000788.SZ |
| Listed Date | 6/16/1997 |
| Chairman | Song Jinsong. |
| CEO | Yuan Pingdong. |
| Website | www.pku-hc.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
